Establishing a Global Standard for Measuring Outcomes in Dengue Treatment Trials

A groundbreaking development in dengue research has led to the publication of the first global standard for measuring outcomes in dengue treatment trials. Released on October 7, 2025, in the esteemed journal The Lancet Infectious Diseases, this standard aims to unify how clinical trials evaluate and report results related to dengue interventions. The initiative was a collaborative effort led by researchers from King's College London and the University of Oxford, addressing a long-standing issue where differing measurement criteria hindered the comparison and synthesis of trial data.

Dengue, a viral disease transmitted primarily by Aedes mosquitoes, remains the most rapidly spreading mosquito-borne viral infection worldwide. With nearly half the global population at risk, the disease's prevalence is escalating due to climate change, urbanization, increased human mobility, and expanding mosquito habitats. Notably, recent reports indicate a surge in dengue cases across Europe, with the European Centre for Disease Prevention and Control (ECDC) noting a peak of 304 locally transmitted cases in 2024.

Currently, there are no specific antiviral treatments for dengue, which underscores the urgency for efficient drug development and evaluation processes. However, varying outcome measures across different clinical studies have posed challenges in comparing findings, thereby slowing progress toward effective therapies. The newly proposed standard includes a core outcome measurement set developed through an extensive international Delphi consensus involving 36 countries, incorporating insights from individuals directly affected by dengue. This approach ensures that the outcomes reflect not only clinical priorities but also patient experiences.

The establishment of a harmonized set of outcomes is expected to accelerate the evaluation of potential treatments, assist regulatory agencies, and guide future clinical trial designs. Experts emphasize that this consensus strengthens the scientific value of research data and supports global health initiatives. As Daniel Munblit from King's College London explains, "With dengue spreading rapidly across continents, we urgently need new treatments. This global standard provides the clarity regulators and researchers require to evaluate therapies faster and make them more widely accessible." Similarly, Sophie Yacoub from the University of Oxford highlights the significance of this advance: "Bringing together a global consensus on clinically relevant outcomes is a major step forward for dengue therapeutics."

Overall, this initiative marks a pivotal move in dengue research, aiming to streamline clinical trials and hasten the development of effective treatments for this growing health threat.